Trial Profile

A first-in-human, Phase 1a clinical trial of GMI-1687 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GMI 1687 (Primary)
Indications Inflammation; Vaso-occlusive crisis
Focus Adverse reactions; First in man
Sponsors Crescent Biopharma; GlycoMimetics

Most Recent Events

16 Jun 2025 According to a Crescent Biopharma media release, GlycoMimetics has been merged with Crescent Biopharma. The combined company will operate under the name Crescent Biopharma.
04 Jan 2024 According to a GlycoMimetics media release, data analysis is ongoing, with full study results to be presented at an upcoming medical meeting.
04 Jan 2024 Results presented in a GlycoMimetics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com